medigraphic.com

2023, Number 3

Next >>

Rev Mex Anest 2023; 46 (3)

Opioid crisis in Mexico

Covarrubias-Gómez A, Esquer-Guzmán HM, Carrillo-Torres O, Carmona-Rodríguez JL, Ramos-Guerrero JA, Soto-Pérez CE, García-Andreu J, Vega-Blancas JL, Gutiérrez-Salmerón C

Language: Spanish
References: 29
Page: 161-165
PDF size: 168.65 Kb.





REFERENCES

  1. Cleary J, De Lima L, Eisenchlas J, Radbruch L, Torode J, Cherny NI. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Latin America and the Caribbean: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol. 2013;24:xi41-xi50. doi: 10.1093/annonc/mdt502.

  2. Covarrubias-Gómez A, Templos-Estebán LA, Esquer-Guzmán HM, Carrillo-Torres O, Pavón-Sánchez RA, Arriaga-Morales E, et al. Reflexiones sobre el uso de opioides para el tratamiento del dolor crónico no-oncológico en México. Rev Mex Anest. 2019;42:312-314. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=89627

  3. Richards GC, Aronson JK, Mahtani KR, Heneghan C. Global, regional, and national consumption of controlled opioids: a cross-sectional study of 214 countries and non-metropolitan territories. Br J Pain. 2022;16:34-40. doi: 10.1177/20494637211013052.

  4. Covarrubias-Gómez A, Guevara-López U, De Lille-Fuentes R, Ayón-Villanueva H, Gaspar-Carrillo SP, Nuche-Cabrera E, et al. Primera cumbre nacional de delegados de la Asociación Mexicana para el Estudio y Tratamiento del Dolor. Rev Mex Anest. 2014;37:142-147. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=50154

  5. Covarrubias-Gómez A, Gaspar-Carrillo SP, Domínguez-Ocadio G, Reyes-Chiquete D, González-Cázares AI, De los Reyes-Pacheco VA, et al. Tercera Cumbre Nacional de Delegados y Vocales de la Asociación Mexicana para Estudio y Tratamiento del Dolor (AMETD). Rev Mex Anest. 2021;44:110-116. doi: 10.35366/99014.

  6. Human Rights Watch. Care when there is no cure: ensuring the right to palliative care in Mexico. USA: Human Rights Watch Press; 2014. Available in: https://www.hrw.org/news/2014/10/24/mexico-needless-suffering-end-life

  7. Fischer B, Pang M, Jones W. The opioid mortality epidemic in North America: do we understand the supply side dynamics of this unprecedented crisis? Subst Abuse Treat Prev Policy. 2020;15:14. doi: 10.1186/s13011-020-0256-8.

  8. Fischer B, Varatharajan T, Shield K, Rehm J, Jones W. Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada. Drug Alcohol Depend. 2018;189:76-79. doi: 10.1016/j.drugalcdep.2018.04.024.

  9. Surratt H, Kurtz S, Cicero T, Dart R, Baker G, Vorsanger G. Street prices of prescription opioids diverted to the illicit market: data from a national surveillance program. J Pain. 2013;14:S40. doi: 10.1016/j.jpain.2013.01.455.

  10. Ventafridda V, Saita L, Ripamonti C, De Conno F. WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React. 1985;7:93-96.

  11. Levy N, Sturgess J, Mills P. 'Pain as the fifth vital sign' and dependence on the 'numerical pain scale' is being abandoned in the US: why? Br J Anaesth. 2018;120:435-438.

  12. Knaul FM, Farmer PE, Krakauer EL, De Lima L, Bhadelia A, Jiang Kwete X, et al. Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report. Lancet. 2018;391:1391-1454. doi: 10.1016/S0140-6736(17)32513-8.

  13. Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol. 2013;75:60-78. doi: 10.1111/j.1365-2125.2012.04317.x.

  14. Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012;6:11-16. doi: 10.1177/2049463712438493.

  15. Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology. 2018;134:121-132. doi: 10.1016/j.neuropharm.2017.10.016.

  16. Velagapudi V, Sethi R. Illicit non-pharmaceutical fentanyl and its analogs: a short review of literature. Kans J Med. 2023;16:25-27. doi: 10.17161/kjm.vol16.18555.

  17. Hasegawa K, Minakata K, Suzuki M, Suzuki O. Non-fentanyl-derived synthetic opioids emerging during recent years. Forensic Toxicol. 2022;40:234-243. doi: 10.1007/s11419-022-00624-y.

  18. Aoki Y, Kato H, Fujimura N, Suzuki Y, Sakuraya M, Doi M. Effects of fentanyl administration in mechanically ventilated patients in the intensive care unit: a systematic review and meta-analysis. BMC Anesthesiol. 2022;22:323. doi: 10.1186/s12871-022-01871-7.

  19. Wang DD, Ma TT, Zhu HD, Peng CB. Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials. J Cancer Res Ther. 2018;14:S14-S21. doi: 10.4103/0973-1482.171368.

  20. Derry S, Stannard C, Cole P, Wiffen PJ, Knaggs R, Aldington D, et al. Fentanyl for neuropathic pain in adults. Cochrane Database Syst Rev. 2016;10:CD011605. doi: 10.1002/14651858.CD011605.pub2.

  21. Rogríguez D, Urrutia G, Escobar Y, Moya J, Murillo M. Efficacy and safety of oral or nasal fentanyl for treatment of breakthrough pain in cancer patients: a systematic review. J Pain Palliat Care Pharmacother. 2015;29:228-246. doi: 10.3109/15360288.2015.1047554.

  22. Wang C, Lassi N. Combating illicit fentanyl: will increased Chinese regulation generate a public health crisis in India? Front Public Health. 2022;10:969395. doi: 10.3389/fpubh.2022.969395.

  23. Han Y, Yan W, Zheng Y, Khan MZ, Yuan K, Lu L. The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. Transl Psychiatry. 2019;9(1):282. doi: 10.1038/s41398-019-0625-0.

  24. Friedman J, Godvin M, Molina C, Romero R, Borquez A, Avra T, et al. Fentanyl, heroin, and methamphetamine-based counterfeit pills sold at tourist-oriented pharmacies in Mexico: an ethnographic and drug checking study. medRxiv [Preprint]. 2023;2023.01.27.23285123. doi: 10.1101/2023.01.27.23285123.

  25. Friedman J, Bourgois P, Godvin M, Chavez A, Pacheco L, Segovia LA, et al. The introduction of fentanyl on the US-Mexico border: An ethnographic account triangulated with drug checking data from Tijuana. Int J Drug Policy. 2022;104:103678. doi: 10.1016/j.drugpo.2022.103678.

  26. Fleiz C, Arredondo J, Chavez A, Pacheco L, Segovia LA, Villatoro JA, et al. Fentanyl is used in Mexico's northern border: current challenges for drug health policies. Addiction. 2020;115:778-781. doi: 10.1111/add.14934.

  27. Pasternak GW. Mu opioid pharmacology: 40 years to the promised land. Adv Pharmacol. 2018;82:261-291. doi: 10.1016/bs.apha.2017.09.006.

  28. Carcamo-Cavazos V, Cannesson M. Opioid-free anesthesia: the pros and cons. Adv Anesth. 2022;40:149-166. doi: 10.1016/j.aan.2022.07.003.

  29. Covarrubias-Gómez A. Indicadores de calidad en la práctica de la anestesiología. Rev Mex Anest 2018;41:79-82. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=79472




2020     |     www.medigraphic.com